Hemosure^®, an one-step, easy to use product developed by Hemosure, Inc. based on its years of clinical study, is the latest technological breakthrough in Immunological Fecal Occult Blood Testing (IFOBT), and it is both FDA approved and CLIA waived. Hemosure^® employs a unique combination of monoclonal and polyclonal antibodies to detect only human blood in stool. As a result, abstinence of food and drug before taking this test is no longer necessary. These advantages can significantly enhance patient compliances.

In addition to the inherent specificity and sensitivity, Hemosure^® test can be performed by health care providers in hospitals, labs and private practices. No need to send fecal samples to the laboratory. Doctors can easily, quickly and accurately read the test results in less than 5 minutes. This new technology has greatly improved specificity, sensitivity, accuracy and cost-effectiveness of the fecal occult blood tests.

The Hemosure one-step immunological
fecal occult blood test is a qualitative, sandwich dye conjugate immunoassay and employs a unique combination of monoclonal and polyclonal antibodies to selectively identify hemoglobin in test samples with a high degree of sensitivity. In less than five minutes, elevated levels of human hemoglobin as low as 0.05ugHb/ml can be detected and positive results for high levels of hemoglobin can be seen in the test as early as one or two minutes.

Contact:  Matthew Keough
eMail: mwk@eMedicalSource.com
Phone: 302.345.7645